Technical Analysis for ZIOP - ZIOPHARM Oncology Inc

Grade Last Price % Change Price Change
grade B 4.29 -2.28% -0.10
ZIOP closed down 2.28 percent on Monday, May 20, 2019, on 58 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ZIOP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -2.28%
Bollinger Band Squeeze Range Contraction -2.28%
NR7 Range Contraction -2.28%
Bollinger Band Squeeze Range Contraction -5.09%
Inside Day Range Contraction -5.09%
Bollinger Band Squeeze Range Contraction -6.13%

Older signals for ZIOP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company's portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.
Medicine Biopharmaceutical Cancer Melanoma Cancer Therapies Metastatic Breast Cancer Metastatic Melanoma Metastatic Small Cell Lung Cancer Neoplasms
Is ZIOP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.0
52 Week Low 1.56
Average Volume 1,692,335
200-Day Moving Average 3.0196
50-Day Moving Average 4.1744
20-Day Moving Average 4.426
10-Day Moving Average 4.423
Average True Range 0.2715
ADX 22.45
+DI 18.2385
-DI 17.9333
Chandelier Exit (Long, 3 ATRs ) 4.0255
Chandelier Exit (Short, 3 ATRs ) 4.7845
Upper Bollinger Band 4.7323
Lower Bollinger Band 4.1197
Percent B (%b) 0.28
BandWidth 13.84094
MACD Line 0.0861
MACD Signal Line 0.1244
MACD Histogram -0.0383
Fundamentals Value
Market Cap 603.31 Million
Num Shares 141 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -8.58
Price-to-Sales 98.61
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.59
Resistance 3 (R3) 4.62 4.55 4.54
Resistance 2 (R2) 4.55 4.47 4.54 4.52
Resistance 1 (R1) 4.42 4.43 4.39 4.39 4.51
Pivot Point 4.35 4.35 4.33 4.34 4.35
Support 1 (S1) 4.22 4.27 4.19 4.19 4.07
Support 2 (S2) 4.15 4.23 4.14 4.06
Support 3 (S3) 4.02 4.15 4.04
Support 4 (S4) 3.99